People facing Alzheimer’s disease long for more time. More memories. More days of feeling like nothing has changed. But the heartbreaking reality is that all these things are stripped away, often with little warning.
That’s why the UW Initiative to End Alzheimer’s (IEA) is pioneering the most advanced research initiatives and treatments to give people and their families hope for the future.
Read the Summer 2023 ‘News for Memorable Friends’ online and find the latest news and upcoming events.
Helen C. Kales, MD, presented the keynote address at the 2023 Dr. Daniel I. Kaufer Lecture Series, an endowed educational program devoted to shaping future generations of dementia care professionals.
On June 8, 2023, Wisconsin Governor Tony Evers and First Lady Kathy Evers welcomed people living with dementia and their caregivers, and representatives from community organizations, to dementia friendly events at the Wisconsin Executive Residence. …
On March 11, the Anchor Bay Bar and Grill in Wisconsin Rapids, WI, hosted its 2023 Shamrock Shuffle raising over $16,000 for the UW Initiative to End Alzheimer’s.
Nathaniel Chin, MD, was featured in the latest issue of Quarterly magazine. In the article “How Grief Transformed Me,” Chin discusses how learning of his father’s Alzheimer’s disease diagnosis altered his professional trajectory.
Dave Adam continues to be a champion for Alzheimer’s disease research. Dave is a Wisconsin man who cycled across Canada last year to help raise funds for Alzheimer’s disease programs at UW–Madison. This year he’s going down under to Australia and plans to bike 2,500 miles to support the UW Initiative to End Alzheimer’s.
The UW Initiative to End Alzheimer’s (IEA) is pleased to announce the IEA Innovation Fund, providing project support for researchers from the Wisconsin Alzheimer’s Disease Research Center (ADRC) or Wisconsin Alzheimer’s Institute (WAI). The IEA Innovation Fund will help advance the University of Wisconsin–Madison’s Alzheimer’s disease researchers’ most promising ideas by providing an open door to funding opportunities that foster translational, innovative and inclusive advancements in Alzheimer’s disease research.
In January, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway to treat Alzheimer’s disease. Nathaniel Chin, MD, recently interviewed Cynthia Carlsson, MD, MS, and Sterling Johnson, PhD, to inform people about the research behind the new Alzheimer’s treatment, the drug’s benefits and risks, and more.
Carey Gleason, PhD, MS, and her research team’s African Americans Fighting Alzheimer’s in Midlife (AA-FAIM) study is entering its second, five-year cycle and they are focused on making Alzheimer’s research more inclusive.